Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc
February 4, 2020
- February 4, 2020
- 8:30 AM - 5:00 PM ET
January 13, 2022
FDA announces the release of a white paper and technical appendices on testing methods for asbestos in cosmetic products containing talc.
- Constituent Update: FDA Releases White Paper on Testing Methods for Asbestos in Cosmetic Products Containing Talc
- FDA News Release: FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products
- IWGACP Scientific Opinions on Testing Methods for Asbestos in Cosmetic Products Containing Talc (including Talc Intended for Use in Cosmetics)
FDA held a public meeting on testing methods for asbestos in talc and cosmetic products containing talc on February 4, 2020 at the FDA White Oak Campus (10903 New Hampshire Ave, The Great Room, Building 31, Silver Spring, Md. 20993).
The purpose of the public meeting was to discuss and obtain scientific data and information on topics related to testing methodologies, terminology, and criteria that can be applied to characterize and measure asbestos and other potentially harmful elongate mineral particles (EMPs) that may be present as contaminants in talc and consumer products, including cosmetics, containing talc as an ingredient.
The meeting included discussions of key topics, such as:
- a federal interagency working group’s preliminary recommendations related to terminology and definitions of asbestos and other EMPs of health concern; and
- scientific data and information related to methodologies, terminology and criteria that can be used in the development of standardized testing methods to improve sensitivity, consistency, and inter-laboratory concurrence of asbestos testing.
Recordings & Transcript
- Recording Part 0
- Recording Part 1
- Recording Part 2
- Recording Part 3
- Full Meeting Transcript (PDF: 7.33MB)
You may view electronically submitted comments on https://www.regulations.gov/ in docket folder FDA-2020-N-0025.